An interventional study of SHURUI Endoscopic Surgical Robotic System (SR-ENS-600) in Gastric Cancer, sponsored by Hebei Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-11.
Sponsored by Hebei Medical University · Not applicable, Interventional, and Treatment
This clinical study was a prospective, single-center, single-arm exploratory study. Subjects who meet the inclusion criteria will be enrolled in this study, where surgeons will perform single-port robot-assisted gastrectomy, and explore and evaluate the safety and efficacy of this clinical application.
Exclusion Criteria:
SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
Device: SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
The rate of intraoperative complications
Intraoperative complications, including organ injury and vascular injury, were evaluated
Time frame: The day of surgery
The rate of postoperative complications
Postoperative complications, including postoperative bleeding, fever, and incisional infection, were evaluated using the Clavien-Dindo grading system to determine whether the occurrence of complications was related to the study instrument or surgery.
Time frame: Postoperative 30 days
Intraoperative system failure rate
Time frame: The day of surgery
Surgical completion rate
Time frame: The day of surgery
Intraoperative blood loss
Time frame: The day of surgery
Operation time
Time frame: The day of surgery
Preoperative device assembly time
Time frame: The day of surgery
Intraoperative instrument operation error rate
Time frame: The day of surgery
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hebei Medical University